{"id":"84d44cb4b661","type":"article","url":"https://hartvaat.nl/2026/02/12/bcr-abl-tyrosinekinaseremmers-en-het-risico-op-pulmonale-arteriele-hypertensie/","title":"BCR-ABL-tyrosinekinaseremmers en het risico op pulmonale arteriële hypertensie","title_en":"Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design","category":"algemeen","category_label":"Algemeen","professions":["apotheker","cardioloog","internist"],"tags":["aldosteronsynthaseremmers","bloeddrukbehandeling","pcsk9-remmers","pulmonale-hypertensie","ras-remmers"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077764","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077764","authors":["Clément Jambon"],"significance":7,"published":"2026-02-12","source_date":"2026-02-12","image":"","kennis":["https://hartvaat.nl/kennis/vasculair/pulmonale-hypertensie/"],"congress":"","summary_en":"This Circulation study quantified the risk of pulmonary arterial hypertension with second- and third-generation BCR-ABL tyrosine kinase inhibitors used for chronic myeloid leukemia, using French national health database data to characterize this serious drug side effect.","created":"2026-07-03T10:25:07Z","updated":"2026-07-03T13:24:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Met een prevalent new-user design in de Franse nationale gezondheidsdatabase werd het risico op pulmonale arteriële hypertensie vergeleken tussen tweede-/derdegeneratie BCR-ABL-TKI's en imatinib. De studie biedt belangrijke veiligheidsgegevens voor oncologen en cardiologen in de cardio-oncologie.","abstract_original":"BACKGROUND:BCR-ABL tyrosine kinase inhibitors (TKIs) have been increasingly linked to pulmonary arterial hypertension (PAH) since 2009, although supporting evidence is limited. Our objective was to evaluate the risk of PAH associated with second- and third-generation BCR-ABL TKIs compared with imatinib in adults.METHODS:We employed a prevalent new-user design that emulates a randomized trial within the French national health care database population between 2008 and 2024. Thus, subjects initiating a second- and third-generation BCR-ABL TKI were matched on time and propensity score with users of the first-generation BCR-ABL TKI, imatinib. Patients were followed to occurrence of the primary outcome (ie, new onset of PAH), switch to another BCR-ABL TKI, death from any cause, end of registration within the database, or end of the study period, whichever came first. Hazard ratios (HRs) and 95% CIs were estimated using Cox proportional hazards regression models, and incidence rates and corre"}